Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PAHC files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsPhibro Animal Health reports 10% Q3 sales growth, raises FY2026 guidance midpoint
Filed May 6, 2026 · Period ending May 6, 2026 · ~1 min read
Key Changes
-
high
Q3 net sales rose 10% to $383.5M, driven by 13% growth in Animal Health segment; adjusted EBITDA up 11% to $60.8M and adjusted diluted EPS increased 19% to $0.76.
Item 2.02 — Results of Operations and Financial Condition verify on EDGAR → -
high
Company raised FY2026 guidance ranges, now expecting net sales of $1.46B–$1.50B (14% growth at midpoint) and adjusted EBITDA of $247M–$255M (37% growth at midpoint).
Item 2.02 — Results of Operations and Financial Condition verify on EDGAR → -
medium
Expanded revolving credit facility by $125M to $435M total capacity on April 28, providing enhanced operating flexibility and strengthened liquidity.
Item 2.02 — Results of Operations and Financial Condition verify on EDGAR → -
medium
Disclosed a regulatory development in Brazil affecting certain antimicrobial products after quarter end; no details on nature, timing, or financial impact provided.
Item 2.02 — Results of Operations and Financial Condition verify on EDGAR → -
low
Launched Sustainable Solutions Platform including VERRATAIN™ Verified Sustainability Solutions product line on May 5.
Item 2.02 — Results of Operations and Financial Condition verify on EDGAR →
Summary
Phibro Animal Health delivered strong third-quarter results with 10% sales growth to $383.5 million and 19% adjusted EPS growth to $0.76, driven primarily by robust demand across its Animal Health segment (medicated feed additives, nutritional specialties, and vaccines).
The company raised the lower end of its full-year guidance, lifting the midpoint for both revenue (to $1.48B, implying 14% growth) and adjusted EBITDA (to $251M, implying 37% growth). Management cited strong year-to-date performance and improved visibility for the remainder of fiscal 2026. The credit facility expansion to $435 million provides additional financial flexibility as the company scales operations.
However, investors should monitor two post-quarter developments: a regulatory change in Brazil affecting antimicrobial products (details not yet disclosed) and the launch of a new sustainability-focused product platform. The Brazilian regulatory matter warrants attention given the region's importance to animal health markets, though the filing provides no specifics on scope or financial impact. Overall, the quarter demonstrates operational momentum with guidance reflecting management confidence in sustained growth through June 30 fiscal year-end.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Phibro Animal Health announced Q3 FY2026 results and updated FY2026 guidance via press release.
Added in current filing · verify on EDGAR →
On May 6, 2026, Phibro Animal Health Corporation issued a press release announcing its operating results for the fiscal quarter ended March 31, 2026 and its financial guidance for the fiscal year ending June 30, 2026.
The company disclosed operating results for the fiscal quarter ended March 31, 2026 (Q3 FY2026) and provided updated financial guidance for the full fiscal year ending June 30, 2026. The specific financial metrics are contained in the press release exhibit, which is furnished but not filed with the SEC.
Event · Exhibit 99.1
Phibro reported Q3 FY2026 results with 10% sales growth to $383.5M, raised FY2026 guidance, and expanded its revolving credit facility by $125M.
Added in current filing · view on EDGAR →
Net sales of $383.5 million, an increase of $35.7 million, or 10% -Net income of $24.0 million, an increase of $3.1 million, or 15% -Diluted earnings per share of $0.59, an increase of $0.08, or 16% -Adjusted EBITDA of $60.8 million, an increase of $5.9 million, or 11% -Adjusted net income of $31.2 million, an increase of $5.0 million, or 19% -Adjusted diluted EPS of $0.76, an increase of $0.12, or 19%
Phibro reported strong Q3 results for the three months ended March 31, 2026, with net sales rising 10% to $383.5 million and adjusted EBITDA up 11% to $60.8 million. Growth was driven by a 13% increase in Animal Health sales, supported by robust demand across medicated feed additives (MFAs), nutritional specialties, and vaccines. Net income rose 15% to $24.0 million, and adjusted diluted EPS increased 19% to $0.76.
Added in current filing · view on EDGAR →
On April 28, 2026, our credit agreement was amended to increase the borrowing capacity of our revolving credit facility by $125 million, from $310 million to an aggregate commitment of $435 million. The expanded borrowing capacity provides the Company with enhanced operating flexibility.
Phibro expanded its revolving credit facility by $125 million through an oversubscribed process, increasing total borrowing capacity from $310 million to $435 million. The amendment occurred on April 28, 2026, shortly after quarter end. Management stated this provides enhanced operating flexibility and strengthens the company's liquidity position.
Added in current filing · view on EDGAR →
After quarter end, we announced a regulatory development in Brazil affecting certain antimicrobial products.
Phibro disclosed a regulatory development in Brazil affecting certain antimicrobial products, announced after the quarter ended March 31, 2026. The filing provides no further detail on the nature, timing, or financial impact of this regulatory change. Investors should monitor subsequent disclosures for specifics on how this affects the company's Brazilian operations and antimicrobial product sales.
Show 1 minor / wording change
Added in current filing · view on EDGAR →
And finally yesterday, we announced the launch of our Sustainable Solutions Platform, including the introduction of VERRATAIN™ Verified Sustainability Solutions.
Phibro announced the launch of its Sustainable Solutions Platform, including a new product line called VERRATAIN™ Verified Sustainability Solutions. The announcement was made on May 5, 2026 (the day before this 8-K filing). No financial details or market impact projections are provided in this filing.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 2, 2026 · How we verify